



Federation of Chinese Medicine &
Acupuncture Societies of Australia Ltd.
澳洲全國中醫藥針灸學會聯合會 (National Body)

FCMA

ACN: 104 651 523 ABN: 70 199 744 719

All correspondence:
6 Paisley Street
Footscray Victoria 3011
Australia

Tel: +61 3 9689 2678
Fax: +61 3 9689 0872
+61 3 9802 4261

Email: contactus@fcma.org.au
tchiangl@fcma.org.au
Web: <http://www.fcma.org.au>

27 April 2020

To: TGA Scheduling Committee

medicines.scheduling@health.gov.au

chemicals.scheduling@health.gov.au

Dear Madam/Sir


Re: Letter of Support

In accordance with the regulations, we wish to make a public submission on one of the scheduling proposals referred to the Joint Advisory Committee on Medicines and Chemicals Scheduling (Joint ACMS-ACCS #25): Cannabidiol (CAS no. 13956-29-1).

We write in strong support of the application to remove hemp-based CBD (where CBD comprises 98% or more of the total cannabinoids and where there is less than or equal to 0.2% THC in such products), from Schedule 4 of the SUSMP and instead regulate it as a complementary medicine, on the Australian Register of Therapeutic Goods. The safety profile is comparable to many other herbal medicines which are regulated as complementary medicines. The WHO Expert Committee has recommended to the United Nations that CBD be removed from international drug control completely.

Removal of hemp-based CBD from the SUSMP, with the appropriate labelling commensurate with any identified risks (for example, the potential to interact with specific epilepsy medications), will significantly increase the level of access to consumers, in line with other western countries where CBD products are readily available to consumers.

Yours sincerely



Professor Tzi Chiang Lin PhD

President, FCMA